Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -1.09% 22.75 97,790 11:28:07
Bid Price Offer Price High Price Low Price Open Price
22.00 23.50 23.00 22.75 23.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services -29.49 -7.71 115
Last Trade Time Trade Type Trade Size Trade Price Currency
16:28:42 O 75,000 22.50 GBX

Advanced Oncotherapy (AVO) Latest News (1)

More Advanced Oncotherapy News
Advanced Oncotherapy Investors    Advanced Oncotherapy Takeover Rumours

Advanced Oncotherapy (AVO) Discussions and Chat

Advanced Oncotherapy (AVO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-10-06 15:28:4322.5075,00016,875.00O
2022-10-06 15:25:4422.138,5321,887.71O
2022-10-06 14:14:4622.752,500568.75O
2022-10-06 13:32:5722.1043195.25O
2022-10-06 12:28:4522.754,343988.03O
View all Advanced Oncotherapy trades in real-time

Advanced Oncotherapy (AVO) Top Chat Posts

Top Posts
Posted at 06/10/2022 09:20 by Advanced Oncotherapy Daily Update
Advanced Oncotherapy Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AVO. The last closing price for Advanced Oncotherapy was 23p.
Advanced Oncotherapy Plc has a 4 week average price of 22p and a 12 week average price of 20.50p.
The 1 year high share price is 39.50p while the 1 year low share price is currently 20.50p.
There are currently 507,231,209 shares in issue and the average daily traded volume is 152,058 shares. The market capitalisation of Advanced Oncotherapy Plc is £115,395,100.05.
Posted at 03/8/2022 09:09 by daijavu
Does anyone remember AVO's massive reverse split of 2016? The share price had been hovering around 20p for quite a while when the BoD announced their brilliant plan to make the share price 'easier to understand'. They cut everyone's share holding by 25 times. so that if you owned, say, 1,000 shares before the reverse split, you suddenly owned just 40 shares after it. But the share price immediately went up to £5 a share so you didn't lose any money. Not at first. The BoD then went on to gradually increase the number of shares through fund raisings, causing massive dilutions that have brought the share price back down to around 20p. I wonder what they'll do next?
Posted at 07/7/2022 01:48 by daijavu
It's almost like the good old days back in 2016 or thereabouts when LIGHT was just a couple of months from full development and AVO had about seven contracts for Chinese hospitals where LIGHT was to be installed within a year or two. They even had a grand contract signing ceremony in China attended by the then PM David Cameron. They were wonderful, heady days, full of promise, when the share price was around £4. I was lucky. I sold just before the share price collapsed. Many others weren't so lucky. I wonder if we're in for a repeat performance? We should soon know.
Posted at 28/6/2022 09:03 by gerhart
Could just be me, but every other week seems to bring news of a new fund raise/share issue/dilution. Does no one in the management do financial planning and get it out of the way once every six months/year? Or would the size of the need be so clearly apparent then. Still, institutions are still prepared to give, so maybe a small vote of confidence. We wait, we hope, we'll see the outcome - sometime!
Posted at 04/11/2021 07:45 by altom
I cannot remember any other placing well above mkt price, like AVO. This must be positive news imho. I expect things to be very different by Easter. I am LTH and have been v.disappointed before, but surely this time……………
Posted at 11/8/2021 10:52 by uncleoswald
The last post was correct..... They did need a large injection of cash. But to raise it at a price above the current share price is surprising and unusual, but very good for the share price!!
Posted at 06/7/2021 21:46 by daijavu
Hi Twirl and robbiekeane I was a LTH of AVO until I realised just how unreliable and untrustworthy the BoD are. I sold at 50p about 3 years ago. I'm now invested in a swathe companies, most of which are doing well. The two things that keep me interested in AVOare LIGHT itself and the fact that the original main shareholders have never sold. It is not impossible that we might see a repeat of 2018, with LIGHT not operational this year and the BoD issuing a revised development schedule early next year. Apart from that I agree that AVO probably needs a big injection of capital to manufacture and sell LIGHT in sufficient quantities to make the sort of profits we want to see.
Posted at 08/6/2021 00:15 by daijavu
robbiekeane I don't know how long you've been an AVO watcher. If it's been as long as I have you would know that this is not new news. AVO has been here before. Several times. It came to nothing each time. I'm not saying that LIGHT will never work but I have had enough experience of the AVO BoD to want to see the money before I put any more of mine in. It might be later this year or it might be next year or it might be in five or ten years time. What is certain is that we are not there yet and I am not going to take any notice of yet another LOI or yet another of the many contracts that AVO have had and failed to meet. You are welcome to put your money in, if that is your choice.
Posted at 05/6/2021 11:24 by robbiekeane
Broker note (house)... AVO Advancing to Sales Advanced Oncotherapy (LSE: AVO) After six- seven years and over £130m investment in intense technical development the next generation of proton beam therapy (PBT) machine, today AVO took a significant commercial step forward. As it is announced that AVO have signed an LOI (Letter of Intent) with Saba Partners to purchase a three- treatment room LIGHT system for around £75.5m. The system is to be installed at Glion in Switzerland which has been acquired by Saba Partners who are building a medical centre of excellence there. This is subject to a CE mark which is should be a mere formality and well on track for the LOI to become binding by March 2022. Proton Beam is a well-established cancer treatment which until now has been rationed by the prohibitive costs. AVO’s technology, inspired by Cern of Geneva, significantly reduces the costs of this life saving treatment and there is significant potential market for the LIGHT system where it is estimated that 4,000 proton therapy centres are required worldwide to meet the demand while only 95 facilities currently exist. Working with Saba Partners over time there is the potential make the LIGHT system available to countries within the Gulf region. Other such deals seem likely and as the technical milestones are passed the higher AVO’s value becomes, This prospect is not reflected in the price at 38p and a market cap of £129m. Buy for the medium term.
Posted at 03/6/2021 09:21 by daijavu
Hi twirl. I didn't realise you were still around. Nothing much seems to have changed with AVO since the old days we lived through with them back around 2016. Where did all those contracts and all that cash disappear to? Today they've announced yet another contract. Subject to them ever getting LIGHT to work, of course. We both have painful memories of the rock solid promises that they were absolutely, definitely, undeniably, on track to have LIGHT up and running by the end of that year. Then, when they eventually admitted that they were still years away from completion, all those Chinese contracts vanished, the share price tanked and Sinophi demanded their money back. I barely got out with my shirt. How much did you lose?
Posted at 29/4/2021 17:38 by robbiekeane
There is a Goetz Partners research note 27/04/2021 on AVO (paid for by Co.) stating Outperformance and a target price of £1.35. It's a detailed piece of work (17 pages). The summary: Our Discounted Cash Flow (DCF) analysis for AVO is shown in CHART 14. We have chosen to value the company on a DCF basis for a number of reasons. Firstly, AVO is a relatively young company in terms of its commercialisation stage in PT and while the technology is older than sixty years, PT has only recently witnessed a significant uptake in clinical adoption. Secondly, AVO’s approach is new and commercially untested. However, the potential for AVO to build a strong position in the future radiation therapy market is significant and we note that the substantial potential upside derived from revenue sharing agreements are not included in our forecasts at this stage. For our DCF, we forecast AVO’s financial performance for 15 years to 2035E to capture the company’s long-term potential. Free cash flows (“FCF”) are discounted, and risk adjusted using a discount factor of 20%, which we feel is appropriate for a company such as AVO, capturing the commercial risk associated with the company achieving our forecasts. This yields a fair value of £1.35 per share, representing c.3.5x upside to current trading levels. Focus remains on commercial momentum growth and upcoming clinical inflection points While there is a growing case for adoption as evidence of treatments where LIGHT could be of benefit such as LEAP, we maintain the view that developing commercial traction remains the key driver for AVO over the next 12 - 18 months. We expect further news flow regarding system sales in line with upcoming clinical development inflection points including first patient treated, although AVO has not recently updated guidance on when this will occur. The LIGHT system is largely de risked from a technology perspective, in our view. However, despite the project being overseen by a number of world-renowned technical experts, and technology originally developed at CERN, we can appreciate why potential customers may not be willing to take a risk on the capital expenditure at this stage due to a lack of real-world evidence for the system. We therefore see the upcoming clinical development milestones as a key inflection point with the first human application of LIGHT likely to trigger an expansion of AVO’s order book.
Advanced Oncotherapy share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AVO
Advanced O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221006 23:08:06